AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11123415
Drug: Hydrogel barrier/repair
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel barrier/repair cream
Trial: 11123415
Drug: Petrolatum-based cream
RxNorm normalized name: PETROLATUM BASE
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petrolatum-based cream
Trial: 8737631
Drug: 1000 mg/d
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/d HR
Trial: 8737631
Drug: 1000 mg/d
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/d and 500 mg/d HR
Trial: 8737631
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d HCE
Trial: 1327655
Drug: S-adenosyl-L-methionine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (oral administration)
Trial: 31110092
Drug: Mifamurtide combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifamurtide combined with postoperative chemotherapy
Trial: 27707990
Drug: Ceftolozane/tazobactam (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane/tazobactam (1.5 g IV every 8 h)
Trial: 27707990
Drug: Levofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (750 mg once daily)
Trial: 27707990
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g IV every 8 h)
Trial: 24157825
Drug: Metformin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (in women without insulin resistance)
Trial: 24157825
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in women without insulin resistance)
Trial: 24157825
Drug: Metformin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (in women with insulin resistance)
Trial: 24157825
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in women with insulin resistance)
Trial: 16953132
Drug: Comprehensive lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive lifestyle modification program (16 weeks, weekly meetings, individually prescribed exercise and diet, stress management, self-monitoring)
Trial: 10839470
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg 12‐hourly for 48 hours
Trial: 10322847
Drug: Jiangtangkang (JTK),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiangtangkang (JTK), 8 g each time, 3 times per day for 2 months
Trial: 10322847
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Glibenclazide for newly discovered NIDDM, no treatment for poorly controlled NIDDM)
Trial: 8489450
Drug: PhXA41 (0.006%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PhXA41 (0.006%) twice daily during week 1 and pilocarpine (2%) three times daily during week 2
Trial: 8489450
Drug: Pilocarpine (2%)
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine (2%) three times daily during week 1 and PhXA41 (0.006%) twice daily during week 2
Trial: 3501692
Drug: Cimetidine and
RxNorm normalized name: Cimetidine and sodium alginate only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine and antacid
Trial: 31718504
Drug: Journal interventions
RxNorm normalized name: Journavx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Journal interventions (e.g., Basic Science Checklist by Stroke)
Trial: 29394998
Drug: heparin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin + a glycoprotein IIb/IIIa inhibitor
Trial: 27117698
Drug: CT-P13 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 (5 mg/kg) administered intravenously every 8 weeks from week 62 to week 102
Trial: 25586332
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) with microskin autografting
Trial: 24257391
Drug: Pudendal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudendal nerve block (PNB) with 0.3 mL/kg 0.25% bupivacaine and 1 µg/kg clonidine
Trial: 24257391
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block (CB) with 1 mL/kg 0.25% bupivacaine and 1 µg/kg clonidine
Trial: 11054030
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (imipramine plus oxybutynin)
Trial: 9202790
Drug: High-density formula
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-density formula (30 kcal/oz) at 145 ml/kg/day
Trial: 9202790
Drug: Low-density formula
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-density formula (24 kcal/oz) at 180 ml/kg/day
Trial: 7972390
Drug: Cocoa capsules
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa capsules (pharmacological equivalent)
Trial: 2537349
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (10 capsules/day, 1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid)
Trial: 2537349
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 capsules of 50% olive oil, 50% corn oil)
Trial: 19392995
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for pollen allergens
Trial: 11577374
Drug: Voriconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (200 mg, b.i.d.)
Trial: 9850026
Drug: BEACOPP (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEACOPP (both standard and escalated dose)
Trial: 28589965
Drug: Exposure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure treatment (2 sessions)
Trial: 23764690
Drug: Gradual titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual titration of paroxetine (2.5 mg on alternate days up to 10 mg in 7 days)
Trial: 23764690
Drug: Abrupt initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abrupt initiation of paroxetine (10 mg)
Trial: 16821647
Drug: New didanosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New didanosine formulation (100 mg tablets)
Trial: 16821647
Drug: Conventional didanosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional didanosine formulation (100 mg tablets)
Trial: 2064401
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin E solution (DL-alpha-tocopherol in dimethyl sulfoxide) applied to three nails for 6 months
Trial: 2064401
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin E solution applied to all nails for an additional 6 months after initial treatment
Trial: 19906801
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (120 mg/d)
Trial: 19906801
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (80 mg/d)
Trial: 17989574
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone (ITD) injections (0.3 mL on days 1, 3, and 5) plus 48 mg methylprednisolone
Trial: 17989574
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone (ITD) injections
Trial: 12444816
Drug: Bromazepam (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam (6 mg/day)
Trial: 2288653
Drug: 3 megaunits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 megaunits of rIFN a‐2b s.c. thrice weekly for 4 months
Trial: 30215171
Drug: Nutritional sodium
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional sodium selenate (0.32 mg, 3 times daily)
Trial: 30215171
Drug: Supranutritional sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supranutritional sodium selenate (10 mg, 3 times daily)
Trial: 26455957
Drug: Vegetable soup
RxNorm normalized name: MALT SOUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable soup with added monosodium L-glutamate (0.5 g/100 ml)
Trial: 24470436
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 6.5 mg/kg/day for 8 weeks
Trial: 24043137
Drug: Famitinib (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famitinib (doses increased from 4 to 30 mg, administered once daily)
Trial: 18838929
Drug: Isotonic fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic fluids (NaCl = 140 mEq/L)
Trial: 18838929
Drug: Hypotonic fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic fluids (NaCl <100 mEq/L)
Trial: 14528702
Drug: Complementary therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary therapies
Trial: 8898646
Drug: Wheat amylase
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat amylase inhibitor preparation (3.0 mg/mL)
Trial: 8898646
Drug: Wheat amylase
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat amylase inhibitor preparation (4.5 mg/mL)
Trial: 8898646
Drug: Wheat amylase
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat amylase inhibitor preparation (6.0 mg/mL)
Trial: 7049504
Drug: Sulindac 400
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac 400 mg once daily (at 9:00 P.M.)
Trial: 7049504
Drug: Sulindac 200
RxNorm normalized name: sulindac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 200 mg b.i.d. (at 9:00 A.M. and 9:00 P.M.)
Trial: 7049504
Drug: Sulindac 200
RxNorm normalized name: sulindac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 200 mg b.i.d.
Trial: 7049504
Drug: Sulindac 400
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac 400 mg once daily
Trial: 17997623
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (age-appropriate movie)
Trial: 15889697
Drug: Enalaprilat (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (0.625 mg) IV infusion
Trial: 12171952
Drug: Anti-H pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-H pylori treatment (omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g, all twice daily for one week followed by placebo for four weeks)
Trial: 12171952
Drug: Anti-H pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-H pylori treatment (omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g, all twice daily for one week followed by omeprazole 20 mg once daily for four weeks)
Trial: 12171952
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily for five weeks
Trial: 9570242
Drug: De Nol
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De Nol 120 mg q.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 2 weeks
Trial: 9570242
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 2 weeks
Trial: 9570242
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 1 week
Trial: 7664546
Drug: CDP571 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP571 0.1 mg/kg
Trial: 7664546
Drug: CDP571 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP571 0.3 mg/kg
Trial: 7664546
Drug: CDP571 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP571 1.0 mg/kg
Trial: 7664546
Drug: CDP571 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP571 3.0 mg/kg
Trial: 831465
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of vaccine (VV)
Trial: 831465
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of vaccine followed by placebo (VP)
Trial: 831465
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of placebo (PP)
Trial: 831465
Drug: One or
RxNorm normalized name: Geone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or two doses of the vaccine
Trial: 28678121
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in the U.S.
Trial: 26218826
Drug: Cryolipolysis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryolipolysis treatment (60-minute cycle followed by a 2-minute massage, then a second 60-minute cycle with 50% treatment area overlap)
Trial: 26218826
Drug: Cryolipolysis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryolipolysis treatment
Trial: 23150149
Drug: NAT2 genotype-guided
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAT2 genotype-guided treatment (PGx-treatment: 7.5 mg/kg for rapid acetylators, 5 mg/kg for intermediate acetylators, 2.5 mg/kg for slow acetylators)
Trial: 23150149
Drug: Conventional standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional standard treatment (STD-treatment: approx. 5 mg/kg of isoniazid for all)
Trial: 16669547
Drug: Prima Difesa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prima Difesa (1 administration) in Group C
Trial: 12897580
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% QD added to pre-existing therapy (group A)
Trial: 11106218
Drug: 5-mg nicotine
RxNorm normalized name: nicotine 0.5 MG/ACTUAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg nicotine patch (placebo)
Trial: 11106218
Drug: 15-mg nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-mg nicotine patch plus nicotine inhaler
Trial: 8975347
Drug: Mepivacain Hydrochloride
RxNorm normalized name: Mepivacaine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacain Hydrochloride with 20 mg of Triamcinolone Hexaacetonide
Trial: 1582237
Drug: Midazolam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.2 mg/kg intravenously) with flumazenil (0.1 to 0.2 mg intravenously)
Trial: 1582237
Drug: Fentanyl (0.002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.002 mg/kg intramuscularly)
Trial: 31790343
Drug: Neuropsychological Assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropsychological Assessment Battery, Screening Module (S-NAB) administered to the S-mTBI group with symptom and test coaching to simulate impairment.
Trial: 30950970
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone (DEX) implant (0.7 mg)
Trial: 30950970
Drug: Aflibercept (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (2 mg, 3 monthly injections as loading phase)
Trial: 30005098
Drug: Natural ingredient‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural ingredient‐based moisturizing cream
Trial: 30005098
Drug: Colloidal oatmeal
RxNorm normalized name: Colloidal Oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal oatmeal moisturizing cream
Trial: 26254019
Drug: Candesartan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan plus standard medical treatment
Trial: 22617632
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) administered in groups of six patients during 12 weekly sessions (n=25)
Trial: 20151341
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine 40 mg followed by propofol 2 mg.kg(‐1) (Group 2PL; n = 30)
Trial: 20151341
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg.kg(‐1) (Group 3P; n = 30)
Trial: 20151341
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg.kg(‐1) (Group 2P; n = 30)
Trial: 20151341
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg.kg(‐1) (Group 3P)
Trial: 20151341
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg.kg(‐1) (Group 2P)
Trial: 20151341
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine 40 mg followed by propofol 2 mg.kg(‐1) (Group 2PL)
Trial: 19140507
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with enalapril and prolonged-release verapamil
Trial: 19140507
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with enalapril and moxonidine
Trial: 11113797
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of ibuprofen taken orally 1 hour before separator placement
Trial: 11113797
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of ibuprofen taken orally immediately after separator placement
Trial: 8336583
Drug: Continuous daily
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous daily regimen of 0.3 mg CEE and one of three low-dose progestogens (medroxyprogesterone acetate 2.5 mg, levonorgestrel 30 micrograms or norethisterone 350 micrograms)
Trial: 8336583
Drug: Continuous daily
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous daily regimen of 0.3 mg CEE and one of three low-dose progestogens
Trial: 8336583
Drug: Norethisterone therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone therapy
Trial: 25033717
Drug: Vaginal intercourse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal intercourse at least twice a week
Trial: 18506512
Drug: Bilateral PEMF
RxNorm normalized name: Pemfexy
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bilateral PEMF treatment (n = 14)
Trial: 18506512
Drug: Postoperative analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative analgesic medication use
Trial: 16170233
Drug: Caffeine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (100 mg in experiments 1 and 3; 150 mg in experiment 2)
Trial: 12544035
Drug: Zinc 50
RxNorm normalized name: Zinc 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc 50 mg daily
Trial: 12544035
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill containing starch
Trial: 10857888
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: three 8-mg doses of ondansetron IV at 4-hour intervals plus dexamethasone 20 mg IV from the start of chemotherapy followed by dexamethasone 5 mg IV every 12 hours.
Trial: 10857888
Drug: Arm B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: three 8-mg doses of ondansetron IV at 24-hour intervals plus dexamethasone 20 mg IV from the start of chemotherapy followed by dexamethasone 5 mg IV every 12 hours.
Trial: 10857888
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A and Arm B (comparison of dosing intervals).
Trial: 1512162
Drug: Cranial irradiation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial irradiation, 24 Gy and i.t. MTX 10 mg/m2, 6 doses (RT group)
Trial: 1512162
Drug: i.t. Ara‐C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.t. Ara‐C 30 mg/m2 and i.t. MTX 10 mg/m2, 10 doses (ChT group)